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MYELOID NEOPLASIA

Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to
genotoxic agents and reduces tumor formation
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Chromodomain helicase DNA-binding protein 4 (CHD4) is an ATPase that alters the
phasing of nucleosomes on DNA and has recently been implicated in DNA doublestranded break (DSB) repair. Here, we show that depletion of CHD4 in acute myeloid
• CHD4 depletion sensitizes
leukemia (AML) blasts induces a global relaxation of chromatin that renders cells more
AML cells but not normal
susceptible to DSB formation, while concurrently impeding their repair. Furthermore,
CD341 progenitors to
CHD4 depletion renders AML blasts more sensitive both in vitro and in vivo to genotoxic
genotoxic agents by relaxing
chromatin and impairing DSB agents used in clinical therapy: daunorubicin (DNR) and cytarabine (ara-C). Sensitization
to DNR and ara-C is mediated in part by activation of the ataxia-telangiectasia mutated
repair.
pathway, which is preliminarily activated by a Tip60-dependent mechanism in response
• CHD4 depletion modulates
to chromatin relaxation and further activated by genotoxic agent–induced DSBs. This
expression of AML cell genes sensitization preferentially affects AML cells, as CHD4 depletion in normal CD341
that regulate tumor formation hematopoietic progenitors does not increase their susceptibility to DNR or ara-C.
in vivo and colony formation in Unexpectedly, we found that CHD4 is necessary for maintaining the tumor-forming
vitro.
behavior of AML cells, as CHD4 depletion severely restricted the ability of AML cells to
form xenografts in mice and colonies in soft agar. Taken together, these results provide
evidence for CHD4 as a novel therapeutic target whose inhibition has the potential to enhance the effectiveness of genotoxic agents
used in AML therapy. (Blood. 2015;126(12):1462-1472)

Key Points

Introduction
Acute myeloid leukemia (AML) is a malignancy that arises from the
impaired differentiation of hematopoietic progenitors, resulting in the
accumulation of immature myeloid blasts in the bone marrow. Despite
advances in our understanding and management of AML, the overall
5-year survival is only 24% due to the low remission and high relapse
rates in older patients and those with complex tumor genotypes.1 Current AML management begins with induction chemotherapy, generally
consisting of an anthracycline, such as daunorubicin (DNR), supplemented with cytarabine (ara-C). Combined DNR/ara-C regimens achieve
overall complete remission (CR) rates ranging from 53% to 58%,2
although recent studies suggest that increasing the DNR dose may
yield tangible beneﬁts to the CR rates and survival of a subset of patients.3,4 Regimens containing various combinations of anthracyclines
and high-dose ara-C also form the foundation of salvage therapy for
patients with relapsed disease.5,6
The anthracycline DNR is a topoisomerase inhibitor that induces
DNA double-stranded breaks (DSBs), which are highly cytotoxic.7
Similarly, the nucleoside analog ara-C also induces DNA damage,
including DSBs, during DNA synthesis through inhibition of DNA
polymerase and incorporation into DNA.8,9 Both normal and leukemic

cells can evade cell death following chemotherapy-induced DSBs by
repairing damage through numerous repair mechanisms. However,
malignant cells tend to be more susceptible to DSB insults due to their
rapid proliferation, deregulated cell-cycle checkpoints, and inactive
DNA repair machinery.10 Recently, the chromatin structure surrounding a DSB has emerged as a key determinant of the kinetics and
mechanism of repair. Thus, chromatin-remodeling enzymes that regulate chromatin architecture have been identiﬁed as key mediators of the
DSB repair process, as they are needed to relax the chromatin structure
surrounding DSBs for efﬁcient repair to occur.11-14
Chromodomain helicase DNA-binding protein 4 (CHD4) is a widely
conserved member of the sucrose nonfermenting 2 superfamily of
chromatin-remodeling ATPases that is capable of altering the phasing
of nucleosomes on DNA.15-18 This ATPase is a core subunit of the
corepressor nucleosome remodeling and deacetylase (NuRD) complex
that has been shown to play a signiﬁcant role in DNA methylationdependent transcriptional repression, particularly the repression of
hypermethylated tumor suppressor genes in cancer.19-21 Additionally,
recent studies found that CHD4 is rapidly recruited to sites of
DSBs,22,23 where it facilitates an E3 ubiquitin ligase RNF8-dependent
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relaxation of the surrounding chromatin to promote the recruitment
of other repair machinery, such as RNF168 and BRCA1.24
In this study, we investigate the dual functionality of CHD4 in the
context of AML. We show that CHD4 is necessary for the efﬁcient
repair of DSBs within AML cells, and that AML cells partially depleted
of CHD4 are more susceptible to clinically used DNA-damaging
agents, such as DNR and ara-C, both in vitro and in vivo. Additionally,
we demonstrate that the depletion of CHD4 in AML cells reduces their
potential to form mouse xenografts and markedly inhibits their ability to
generate colonies. We show that both of these phenotypes are consistent
with gene expression alterations resulting from CHD4 depletion.
Importantly, all of these events occur preferentially in AML cells,
as similar depletion of CHD4 in normal CD341 hematopoietic progenitor cells does not result in similar phenotypes. Taken together,
the present ﬁndings highlight for the ﬁrst time the therapeutic potential of targeting CHD4 in AML.

Methods
Cells
Human AML U937 and MV4-11 cells were described previously.25 OCI-AML3
cells were purchased from Deutsche Sammlung von Mikroorganismen und
Zellkulturen (DSMZ; Braunschweig, Germany). Cells were cultured in RPMI
1640 (Gibco) supplemented with 10% fetal bovine serum (FBS; Atlas) and 2%
penicillin/streptomycin. Cell numbers were measured by a Cellometer Auto T4
(Nexcelom Bioscience).
Isolation of primary cells
This study was approved by the Virginia Commonwealth University (VCU)
Investigational Review Board and samples were collected with patient consent.
Bone marrow was collected from AML patients with high disease load (.90%
blasts in the marrow) and mononuclear cells were isolated by Ficoll-Hypaque
gradient separation as described previously.25 Normal CD341 hematopoietic
progenitor cells were isolated from deidentiﬁed apheresis units discarded by the
VCU Bone Marrow Transplant Unit as described previously.26 All primary cells
were cultured in StemSpan serum-free expansion medium with 13 CC100
cytokine mix (StemCell Technologies) and 2% penicillin/streptomycin.
Short hairpin RNA (shRNA) constructs were created as described previously.26 Brieﬂy, CHD4 target sequences (shCHD4-1: CGGTGAGATCATCCTGTGTGATA; shCHD4-2: GGACCTGAATGATGAGAAACAGA) and the
Tip60 target sequence (CCTCAATCTCATCAACTACTA)27 were cloned into
a green ﬂuorescent protein (GFP)-expressing pRRL.H1.shRNA vector and packaged into a lentivirus through calcium phosphate transfections in 293T cells.
Immunoblotting was performed as described previously.28,29 Blots were
imaged and quantitated using a Li-Cor Odyssey Fc Imager. Primary antibodies
for the antigens studied were obtained from several sources: H3K9ac, H3,
H4K8ac, H4, cleaved-caspase 3, phosphorylated ataxia-telangiectasia mutated
(p-ATM; S1981), and ATM, all from Cell Signaling; CHD4 from Millipore;
poly(ADP-ribose) polymerase (PARP) from Biomol Research Laboratories;
E2F1 from Santa Cruz Biotechnology; and a-tubulin from Calbiochem.
Confocal microscopy was performed on a Zeiss 720 Meta microscope as
previously described.30 Primary antibodies used were against H3K9me3 and
g-H2A.X (Millipore). Images were quantiﬁed using the Velocity Image Analysis
software (PerkinElmer).
Comet assays were performed under neutral conditions using the Trevigen
CometAssay kit with modiﬁcations as previously described.31 Comets were
quantitated by CASPLab Comet Assay software.32
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In vivo studies were approved by the VCU Institutional Animal Care
and Use Committee. Female NOD scid g mice (NSG; The Jackson Laboratory) were engrafted IV via the tail vein with 5 3 106 luciferase-expressing
U937 cells. Tumor progression was monitored by the total radiance generated
within each mouse upon subcutaneous administration of luciferin as measured
by the IVIS 200 imaging system (Xenogen Corporation). Once tumor
engraftment was conﬁrmed, the mice were treated with a previously described
model of the human “7 1 3” induction therapy.33,34 Brieﬂy, this regimen
consisted of 3 consecutive days of Doxorubicin (100 mg/kg; Selleck Chemicals)
and ara-C (33 mg/kg; Selleck Chemicals) given IV by tail-vein injection,
followed by 2 additional days of ara-C (33 mg/kg) given by intraperitoneal
injection.
Colony-forming assays were performed as previously described.28 For AML
cell lines, 5000 cells were suspended in 1 mL of 13 RPMI supplemented with
0.35% agarose (Difco), 10% FBS, and 2% penicillin/streptomycin and plated
into a well of a 12-well plate. Cells were allowed to grow for 14 days and colonies
were identiﬁed as having .50 cells. For CD341 cells, the Methocult H4434
Classic kit (StemCell Technologies) was used.
Microarray analysis was performed using HG-U133Ax2 GeneChips
(Affymetrix). Quality of the hybridization was assessed by examining the
average background, scaling factor, the percentage of probe sets called
present by the detection call algorithm, and the 39:59 ratio for glyceraldehyde3-phosphate dehydrogenase (GAPDH) and ACTIN. Each GeneChip was
independently normalized using quantile normalization and the robust
multiarray average method was applied to probe-set expression summaries.35 For each probe set, a moderated t test was used to make comparisons using the limma Bioconductor package36,37 in the R programming
environment.38 The P values were used in estimating the false discovery
rate (FDR) using the Benjamini and Hochberg method39 and probe sets
having an FDR , 0.05 were considered signiﬁcant. Pathway analysis of the
signiﬁcant probe sets was performed using the Ingenuity Pathway Analysis
software (Qiagen).
Statistical analysis
Results are shown as means 1 standard deviation (SD) unless otherwise stated.
P values were calculated by the Student t test.

Results
CHD4 is necessary for maintaining heterochromatin in
AML blasts

As CHD4 is a chromatin-remodeling ATPase,15-18 we investigated
the effect of CHD4 depletion on the overall chromatin structure of
AML cells. Integration of a CHD4-targeting shRNA (shCHD4-1)
into the AML cell lines U937, MV4-11, and AML-3 by a lentiviral
vector resulted in the robust depletion of the CHD4 protein (supplemental Figure 1A, see supplemental Data available at the Blood
Web site). When compared with control cells in which a scrambled,
nontargeting shRNA was integrated, cells depleted of CHD4 were
found to have a global increase in the euchromatin-associated
acetylation of histone H3 lysine 9 and histone H4 lysine 8 (Figure 1A;
supplemental Table 1) and disruption of heterochromatin-associated
trimethyl-histone H3 lysine 9 foci (Figure 1B). These results indicate
that inhibition of CHD4 function induces a global relaxation of the
chromatin structure in AML blasts.

Cell sensitivity to DNR and ara-C

Depletion of CHD4 renders AML blasts more sensitive to DSB
damage and impairs the repair of DSBs

Cells were incubated with DNR (Sigma-Aldrich) or ara-C (Sigma-Aldrich) for
24 hours and a 7-aminoactinomycin D (7AAD; Sigma-Aldrich) stain read by
a FACSCanto Cell Analyzer (BD) was used to determine cell viability.

Because chromatin-remodeling enzymes have been found to play
key roles in mediating the repair of DSBs,11,14 we investigated
whether CHD4 is involved in DSB repair in AML blasts. We subjected
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Figure 1. CHD4 is necessary for the maintenance of
heterochromatin and the efficient repair of DNA
DSBs in AML blasts. AML cell lines were infected by
lentivirus to integrate either a nontargeting, scrambled
(Sc) shRNA or a CHD4-targeting shRNA. (A) Depletion
of CHD4 leads to a global increase in euchromatinassociated histone H3K9 and H4K8 acetylation. (B)
Depletion of CHD4 also results in a disruption of
heterochromatin-associated histone H3K9me3 foci in
U937 cells as shown by staining with anti-H3K9me3
antibody. (C) U937 cells were exposed to 6 Gy of
radiation to induce DNA DSBs. DSB formation and
repair was monitored over a 4-hour time course using
a neutral comet assay. CHD4-depleted cells displayed
significantly more evidence of DSBs and were delayed
in their repair (n . 50 comets). (D) The results of the
comet assay were confirmed by staining for Y-H2A.X
foci and calculating the fluorescent intensity per nucleus
(n . 60 cells per time point). (E) Representative images
of the Y-H2A.X stain. *P , .05.

U937 cells to 6 Gy of radiation and detected DSBs using a neutral
comet assay over a 4-hour time course (Figure 1C). CHD4-depleted
cells demonstrated signiﬁcantly more evidence of DSBs 1 hour after
radiation exposure, suggesting that inhibition of CHD4 rendered the
cells more susceptible to the formation of DSBs. The tail moment of
control cells returned to baseline after just 2 hours, indicating that
cells expressing wild-type levels of CHD4 are capable of rapidly
repairing radiation-induced DSBs to levels below the detection limits
of the assay. However, the tail moment of the CHD4-depleted cells
remained elevated throughout the 4-hour course of the experiment,
indicating that CHD4 is required for the efﬁcient repair of DSBs in
AML cells.
To conﬁrm our observations from the neutral comet assay, we
performed immunostaining for gH2A.X foci, a histone marker of
DSBs, over the 4-hour time course (Figure 1D-E). Cells depleted of
CHD4 contained a signiﬁcant increase in gH2A.X foci at 0.5 hours
postradiation exposure and the number of foci remained elevated
above that in control cells over the 4-hour time course. Similar
results were obtained for MV4-11 and AML-3 (supplemental
Figure 2).
We then conﬁrmed that the DSBs observed over the 4-hour time
course were not the result of apoptosis, as neither PARP nor caspase-3
cleavage occurred throughout the 4-hour time course (supplemental

Figure 3). Thus, in AML cells, inhibition of CHD4 impedes the repair of
DSBs and increases susceptibility to their formation.
Inhibition of CHD4 renders AML blasts more sensitive to DNR
and ara-C in vitro

Having determined that CHD4 affects the formation and repair of DSB
in AML cells, we hypothesized that AML cells depleted of CHD4
would be more sensitive to the DSB-inducing agents DNR and ara-C.
To test this hypothesis, we incubated the AML cells for 24 hours with
clinically relevant concentrations of either DNR (Figure 2A) or ara-C
(Figure 2B) and the assessed their viability with 7AAD staining. At all
DNR and ara-C concentrations tested, signiﬁcantly more cell death
was observed in the AML cells depleted of CHD4, with some concentrations resulting in as much as a ﬁvefold increase in cell death.
Similar results were obtained when we depleted CHD4 in a primary
AML sample (098-8712-3A). To conﬁrm that the increase in sensitivity
to DNR and ara-C was not the result of an off-target effect of the shRNA
construct used, a second CHD4-targeted shRNA construct (shCHD4-2;
supplemental Figure 1A-B) was tested and induced a similar increase
in sensitivity to DNR (supplemental Figure 4). Thus, knockdown of
CHD4 with 2 independent shRNA constructs enhanced the in vitro
sensitivity of AML cells to DNR and ara-C.
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Figure 2. Inhibition of CHD4 renders AML blasts more sensitive to DNR and ara-C in vitro. U937, MV4-11, and AML-3 human AML cell lines and a primary AML sample were incubated
with various concentrations of (A) DNR or (B) ara-C for 24 hours in vitro. Cell viability was assayed using a 7AAD stain and quantified by flow cytometry. For all AML cells and concentrations of
DNR/ara-C tested, AML cells depleted of CHD4 displayed significantly more cell death compared with controls. P , .05 for every data point tested; n 5 3 biological replicates for each data point.

As DNR is a ﬂuorescent-intercalating agent40 and CHD4 depletion
induces a global relaxation of chromatin in AML blasts, we tested
whether CHD4-depleted cells were more susceptible to DNR intercalation. Incubation of U937 cells for 2 hours with 200 ng/mL DNR
caused signiﬁcantly more DNR ﬂuorescent signal inside the nuclei of
CHD4-depleted cells (supplemental Figure 5). This ﬁnding is consistent
with increased DNR intercalation within CHD4-depleted cells.
Inhibition of CHD4 does not sensitize normal CD341 progenitor
cells to DNR and ara-C

We next investigated whether the increased sensitivity to DNR and ara-C
induced by CHD4 inhibition occurs preferentially in AML blasts.
We depleted CHD4 in CD341 hematopoietic progenitor cells isolated from the mobilized blood of 3 normal donors (supplemental
Figure 1E). Following incubation for 24 hours with DNR and ara-C,
CD341 cells did not display a signiﬁcant increase in sensitivity to
DNR (Figure 3A) or ara-C (Figure 3B).
To gain insight into how CHD4 depletion might preferentially
sensitize leukemic cells, we compared the total endogenous CHD4
protein levels in CD341 cells from the 3 normal donors to that in 3
AML cell lines (U937, MV4-11, AML-3) and blasts isolated from the
bone marrow of 3 different AML patients whose marrow contained
.90% blasts. AML cell lines and primary AML blasts contained on
average ;50% less CHD4 total protein than CD341 cells (Figure 3C;
supplemental Figure 1E). Surprisingly, AML cell lines and primary
AML samples did not have signiﬁcantly different amounts of CHD4
messenger RNA (mRNA) compared with the normal CD341 progenitors,

suggesting that posttranscriptional alterations could account for the
discrepancy in the observed amount of CHD4 protein.
Inhibition of CHD4 sensitizes AML blasts to DNR and ara-C in
a xenograft model

Having demonstrated that depletion of CHD4 preferentially increases
the sensitivity of AML cells to DNR and ara-C in vitro, we tested the
effect of CHD4 depletion in AML cells in vivo. To this end, we used
a previously described mouse xenograft model of the human “7 1 3”
induction regimen33,34 that consists of 5 continuous days of ara-C
treatment and doxorubicin coadministered on days 1 through 3. In this
model, the anthracycline doxorubicin is substituted for the anthracycline DNR used in humans due to the systemic toxicity of the latter in
mice.33 Luciferase-expressing U937 cells were systemically engrafted
by tail-vein injection into NSG mice (n 5 3 mice per condition) and
disease progression was monitored by total radiance (measured in
photons/second/centimeter2/steradian) generated within each mouse
upon subcutaneous administration of luciferin.
The treatment regimen was initiated once a systemic xenograft
was conﬁrmed and mice were reimaged 7 days later, a time we had
previously observed to yield the maximum drug-induced antitumor
effect. Posttreatment, mice engrafted with control cells displayed,
on average, 43% of their total pretreatment radiance. However,
mice engrafted with CHD4-depleted cells displayed only 20% of
their pretreatment radiance (Figure 4A), indicating that AML blasts
depleted of CHD4 are indeed more sensitive to DNR and ara-C
treatment in vivo.
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Figure 3. Inhibition of CHD4 does not sensitize
normal CD341 progenitor cells to DNR and ara-C.
CD341 hematopoietic progenitors were isolated from
the 3 normal donors. Depletion of CHD4 did not significantly increase the sensitivity of the CD341 cells
to either (A) DNR or (B) ara-C. (C) The CD341 cells
were found to contain significantly more endogenous
CHD4 protein than the AML cell lines (U937, MV4-11,
AML-3) and primary AML blasts isolated from the bone
marrow of 3 patients. Interestingly, there was no difference in CHD4 mRNA between the CD341 and AML
cells. *P , .05. N.S., not statistically significant.

Mice were then followed for survival, until a humane end point was
reached (Figure 4B). Untreated mice engrafted with CHD4-depleted
cells survived signiﬁcantly longer than those engrafted with control
cells. The survival of the mice engrafted with CHD4-depleted cells
further improved with the addition of the drug regimen. Once the mice
reached their humane end points, bone marrow was collected and
analyzed. In the marrow of mice that received the shCHD4-depleted
cells, the AML cells retained ;75% knockdown of CHD4 mRNA
compared with cells from the bone marrow of mice containing the
control shRNA (data not shown).
Inhibition of CHD4 improves survival in mice

Despite injection with equivalent numbers of viable leukemic cells
at the same time, mice engrafted with CHD4-depleted cells harbored
signiﬁcantly lower tumor burden than mice engrafted with control cells
when therapy was initiated. CHD4 depletion did not signiﬁcantly alter
the in vitro (supplemental Figure 6) or in vivo (supplemental Figure 7)
proliferation rate, nor did it alter the cell-cycle distribution of the
tested AML cell lines (supplemental Figure 8). Therefore, proliferative
alterations are unlikely to account for the discrepancy in the tumor
burden between mice engrafted with control vs CHD4-depleted cells.
An alternative explanation is that CHD4 depletion reduces the
tumor-forming capacity of the leukemic cells. We performed soft
agar colony-forming assays, as leukemic cells capable of forming
colonies in soft agar have been shown to possess the ability to initiate
disease in vivo.41 Indeed, CHD4 depletion sharply reduced the
formation of AML colonies in soft agar (Figure 5A-B; supplemental
Figure 9), suggesting that CHD4 is required to maintain the full tumorforming ability of these cells.

CHD4 depletion alters expression of genes involved in
tumor formation

To gain insight into the molecular basis for this loss of colony-forming
potential, we performed microarrays to investigate transcriptional alterations that result from the depletion of CHD4. Probe sets were considered to be differentially expressed if the FDR was ,0.05, which resulted
in 1320 and 675 differentially expressed genes in U937 and MV4-11,
respectively. We then used a downstream effects analysis in the Ingenuity
Pathway Analysis (IPA) software to interpret the biological implications
of gene expression alterations (Figure 5C). According to this analysis,
CHD4 depletion resulted in a net decrease in the expression of genes
previously reported to increase the colony-forming potential of tumor
cells and concomitantly induced the expression of genes previously reported to decrease the colony-forming potential of tumor cells. Taken
together, the IPA analysis predicted a signiﬁcant decrease in the colony
formation potential of both U937 and MV4-11 cells.
We then used quantitative polymerase chain reaction to validate the
expression alterations of several genes whose differential expression has
previously been shown to signiﬁcantly alter the colony formation of
AML and hematopoietic stem cells, including Myc and PCGF2.42-44
Consistent with the microarray data, Myc was found to be downregulated
and PCGF2 was found to be upregulated in the CHD4-depleted AML
cells (supplemental Figure 10). An additional 7 genes were also validated
in CHD4-depleted AML cells (supplemental Figure 11). In conjunction
with the IPA analysis, these results indicate that transcriptional alterations
induced by the depletion of CHD4 can at least partially explain the
decrease in colony-forming potential in AML cells.
In contrast to the ﬁndings in AML cells, depletion of CHD4 did not
signiﬁcantly alter the colony-forming potential of CD341 cells isolated
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Figure 4. Inhibition of CHD4 sensitizes AML blasts to
DNR and ara-C in a xenograft model. Equal numbers
of luciferase-expressing Scramble and shCHD4 U937
cells were engrafted into NSG mice by tail-vein injection
and tumor burden was noninvasively monitored by
measuring the total radiance generated upon subcutaneous administration of luciferin. (A) Once a tumor was well
established (as seen in the pretreatment panels), the
mice were treated with 5 continuous days of ara-C, with
concurrent doxorubicin on days 1 through 3. Posttreatment, mice engrafted with control cells were found to
possess 43% of their pretreatment radiance, whereas
mice engrafted with CHD4-depleted cells possessed 20%
(P , .001). (B) The mice were followed for survival.
CHD4 depletion alone resulted in a 7-day improvement in
mouse survival. Treatment with Doxorubicin/ara-C improved the survival of the mice engrafted with CHD4depleted cells by an additional 4 days. *P , .05.

from normal donors (Figure 5D; supplemental Figure 12). Consistent
with this observation, the expression of neither Myc nor PCGF2 was
signiﬁcantly altered in the CHD4-depleted CD341 cells (supplemental
Figure 10).
Inhibition of CHD4 activates the ATM signaling pathway to
induce apoptosis

As AML cells depleted of CHD4 are more sensitive to DSB-inducing
agents, we investigated the role of the ATM pathway. The serine/
threonine kinase ATM is a master regulator of the DSB repair response
and is classically activated by autophosphorylation of serine 1981 in
response to double-stranded DNA breaks.10,45 Recently, the protein
acetyl-transferase Tip60 was found to activate ATM in response to
chromatin relaxation.46 Because depletion of CHD4 led to a global
relaxation of the chromatin structure of AML cells, we hypothesized that

depletion of CHD4 would induce a Tip60-dependent activation of
ATM. Accordingly, a 10-fold increase in the phosphorylation of S1981
on ATM in U937 cells was observed upon the depletion of CHD4.
However, the phosphorylation of ATM remained at control levels upon
concomitant depletion of Tip60 in CHD4-depleted cells (Figure 6A;
supplemental Table 2). This observation indicates that inhibition of
CHD4 does induce a Tip60-dependent activation of ATM.
We next sought to investigate the ATM pathway in AML cells in
response to DNR. As expected, ATM is autophosphorylated in a dosedependent manner in both control and shCHD4 cells. However, a
signiﬁcant increase in the amount of p-ATM was detected at each
DNR concentration tested in CHD4-depleted cells (Figure 6B). Interestingly, depletion of CHD4 also increased the level of total ATM by
threefold. Once active, ATM induces numerous downstream phosphorylation events that signal for cell survival by initiating the repair
of DSBs or it can trigger apoptosis.10,47 E2F1 is a proapoptotic
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Figure 5. CHD4 depletion dramatically decreases the tumor-forming behavior of AML cells and modulates expression of genes associated with tumor colony
formation. CHD4-depleted cells were inhibited in their ability to engraft into the NSG mice. CHD4 depletion severely reduced the ability of U937 and MV4-11 cell lines to form
colonies in soft agar. (A) Representative images (203) of colonies. (B) Quantitation of AML colonies (*P , .05, n 5 3). (C) Microarray arrays were performed to determine the
gene expression alterations associated with CHD4 depletion. Ingenuity Pathway Analysis software was used to interpret the data and predicted a significant decrease in the
colony-forming potential in both U937 and MV4-11 (activation Z score of 22.044 and 22.002, respectively). (D) Depletion of CHD4 in CD341 hematopoietic progenitors
isolated from 3 normal donors did not result in a significant decrease in colony formation.

transcription factor that is stabilized by ATM through phosphorylation
of Serine-31.48 E2F1 is stabilized in U937 cells in a DNR dosedependent manner in control cells (Figure 6C); however, signiﬁcantly
more E2F1 is stabilized in response to DNR in cells partially depleted

of CHD4 (Figure 6D). E2F1 did not undergo a DNR dose-dependent
stabilization when the ATM inhibitor KU60019 was added, indicating that the observed dose-dependent stabilization requires ATM
(Figure 6E). Ultimately, the increased activation of ATM and the
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Figure 6. Inhibition of CHD4 activates the ATM
signaling pathway to induce increased apoptosis.
(A) Depletion of CHD4 in U937 cells induces a significant activation of ATM, which is blocked by the
concurrent depletion of Tip60. (B) Upon addition of
DNR, ATM is activated in a concentration-dependent
manner, with significantly more activation in the CHD4depleted cells. (C) Once active, ATM acts on its downstream targets, including stabilizing the proapoptotic
transcription factor E2F1. E2F1 is stabilized in a DNR
concentration-dependent manner, (D) with significantly
more being stabilized in the CHD4-depleted cells.
(E) This stabilization is diminished upon the addition of
the ATM inhibitor KU60019. (F) Ultimately, in response
to the DNR, CHD4-depleted AML cells display elevated
markers of apoptosis, including PARP and Caspase-3
cleavage.

subsequently increased downstream proapoptotic signaling in response to DNR in CHD4-depleted AML cells resulted in increased
apoptosis compared with control cells (Figure 6F).

Discussion
CHD4 and its associated NuRD complex have emerged as key
mediators of the double-stranded DNA damage repair pathway11,12 and
gene expression, most notably repression of hypermethylated tumor
suppressor genes in cancer.19,20 Here, we describe the ﬁrst study that
examines the interplay of CHD4’s dual functionality in AML. We
observed that the partial depletion of CHD4 in AML cells induces
a global relaxation of the chromatin structure (Figure 1), which is similar
to previous reports in Ramos49 and HeLa50 cell lines. CHD4-depleted
AML cells were also found to be more susceptible to the formation of
DSBs (Figure 1), consistent with evidence that CHD4 protects U2OS
osteosarcoma cells from ionizing radiation22,23,51 and that relaxed
chromatin is more susceptible to the formation of DSBs than condensed
chromatin.52,53 In addition, our results show that the DNA of CHD4depleted cells were more exposed to intercalation by DNR (supplemental Figure 5), consistent with the greater capacity of anthracyclines to
bind nucleosome-free DNA.54 CHD4-depleted AML cells also failed

to efﬁciently repair the resulting genotoxic agent–induced DSBs
(Figure 1). Probing ATM pathway components in CHD4-depleted
AML cells revealed a Tip60-mediated activation of ATM prior to DNA
damage as well as an ATM-dependent stabilization of the proapoptotic
transcription factor E2F1 upon induction of DSBs (Figure 6). Taken
together, these results indicate that targeting CHD4 could increase the
sensitivity of AML cells to genotoxic agents commonly used in therapy
through a combination of increased susceptibility to the formation of
DSBs and inhibition of their repair (Figure 7).
Depletion of CHD4 in 3 AML cell lines and a primary AML patient
sample increased the in vitro sensitivity to clinically relevant concentrations of single-agent DNR and ara-C (Figure 2). Importantly, the
increased sensitivity to DNR and ara-C occurred preferentially in AML
cells, as normal CD341 hematopoietic progenitors partially depleted
of CHD4 did not demonstrate a similar increase in susceptibility
(Figure 3). We hypothesize that the preferential sensitivity of AML
cells to CHD4 depletion may reﬂect disparate levels of endogenous
CHD4 between normal CD341 cells and AML cells, as AML cell lines
and primary AML cells appear to contain signiﬁcantly less total endogenous CHD4 protein compared with normal CD341 progenitor cells
(Figure 3C). It remains uncertain whether the diminished levels of
CHD4 protein in AML cells reﬂect the normal differentiation of myeloid
lineage cells or are associated in a yet-to-be determined way with the
tumorigeneic capacity of AML. In any case, these ﬁndings argue that
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Figure 7. Model of CHD4 enhancement of genotoxic agent-induced apoptosis through DSB repair
inhibition and chromatin relaxation. In AML blasts,
depletion of CHD4 relaxes the chromatin, resulting
in the activation of ATM through Tip60 and thereby
primes the cells for apoptotic signaling. Moreover, the
relaxed chromatin is more susceptible to genotoxic
agent-induced DSBs. Additionally, CHD4-deficient blasts
have impaired DSB repair, resulting in the accumulation
of more DSBs and further activation of ATM through the
classical Mre11, Rad50, NBs1 (MRN) complex. The net
activation of ATM in CHD4-depleted cells increases its
downstream proapoptotic signaling cascade, thereby
resulting in apoptotic cell death.

a threshold level of CHD4 may be required for efﬁcient DSB repair,
implying that leukemia cells containing less endogenous CHD4 may be
more vulnerable to CHD4 inhibition than their normal counterparts.
In a clinically relevant mouse model of induction therapy, NSG
mice engrafted with CHD4-depleted U937 cells displayed increased
drug sensitivity and survival (Figure 4). An unexpected and important
ﬁnding was that depletion of CHD4 signiﬁcantly reduced the tumor
burden of the xenografts, which resulted in an additional treatmentindependent increase in survival. We also observed that depletion of
CHD4 sharply reduces the growth of AML colonies in soft agar, but not
the growth of normal donor CD341 hematopoietic progenitor colonies.
This suggests that a minimal level of CHD4 is necessary for the
maintenance of tumor-forming behavior of leukemic cells, consistent
with evidence that CHD4 and its associated NuRD complex regulate
genes implicated in the tumor-initiating state of glioblastoma.55
The role of CHD4 in AML appears to be quite complex, as it exhibits
a prooncogenic function through its role in tumor formation, but concurrently displays a tumor suppressor function in its facilitation of DSB
repair. We attribute this apparent discrepancy to the diverse roles that
CHD4 fulﬁlls within a cell, including regulating gene expression and
facilitating DNA repair. This exhibition of both prooncogenic and tumor
suppressor properties is shared with other chromatin modiﬁers such as
HDAC156 and EZH257,58 and may reﬂect a general property of epigenetic regulators. Regardless, the data presented here suggest that CHD4
represents a plausible, new therapeutic target in AML. As combinations of anthracyclines and ara-C form the foundation of both AML
induction and salvage therapy, inhibiting CHD4 might enhance the
efﬁcacy of current regimens without increasing the required doses of
these agents. This would be of particular interest for anthracycline-based
regimens, as the maximum lifetime dose of anthracyclines is severely
limited by a cumulative, dose-dependent cardiotoxicity,59 although
study of CHD4 inhibition in cardiac tissue is needed to corroborate
this. Furthermore, the chromatin-relaxation effect of CHD4 inhibition
may have additional implications for anthracycline-based therapy, as
anthracyclines have been found to displace nucleosomes from transcription start sites of genes located in regions of relaxed chromatin
which deregulates the transcriptome and drives apoptosis in AML
cells.60 Thus, inhibition of CHD4 may also potentiate DNA damageindependent mechanisms of anthracycline-mediated antileukemic activities. Finally, given the role of CHD4 in maintaining the tumor-forming
behavior of AML cells, CHD4 inhibition could have broader

implications for disease outcomes in light of the role of tumorforming behavior in disease relapse.41,61-68
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1. Byrd JC, Mrózek K, Dodge RK, et al; Cancer and
Leukemia Group B (CALGB 8461). Pretreatment
cytogenetic abnormalities are predictive of
induction success, cumulative incidence of
relapse, and overall survival in adult patients with
de novo acute myeloid leukemia: results from
Cancer and Leukemia Group B (CALGB 8461).
Blood. 2002;100(13):4325-4336.
2. Tefferi A, Letendre L. Going beyond 7 1 3
regimens in the treatment of adult acute myeloid
leukemia. J Clin Oncol. 2012;30(20):2425-2428.
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